AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02076815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide retard
Description: Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
Study NCT02076815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thromboreductin
Description: Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
Study NCT04269824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention package
Description: Community mobilization and commitment events~* Update factual beliefs~* Establish public commitment~* Update empirical expectations about toilet use~Audio announcements - Disseminate norms-related messages regarding toilet use and ownership~Group level~- Facilitated sex-segregated group meetings to share information and action knowledge through increased social connections~Network-level social media messages - Transmit norms-related messages, and testimonials of adopters through influential social network members~Household-level Counseling visits~* Update empirical expectations of improved sanitation behaviors in their community~* Motivate improved sanitation practices~* Build capacity to achieve exclusive toilet use~Stickers/decals~- Signal adoption of promoted behaviors to community members~Individual-level~* Update empirical expectations of improved behaviors among similar others~* Set goals, track progress and maintain improved behavior
Study NCT00031772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Questionnaire and telephone intervention
Study NCT01962623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IPT-MBD
Description: IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.
Study NCT01962623 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPT-MBD
Description: IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.
Study NCT02517021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-netupitant/Palonosetron
Study NCT02517021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netupitant/Palonosetron
Study NCT02517021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02517021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT05624216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-084
Description: Radiofrequency and targeted pressure energy devices for the treatment of cellulite
Study NCT04114656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available as intravenous (IV) infusion of normal saline (0.9 percent \[%\] sodium chloride solution).
Study NCT04114656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279
Description: GSK3858279 will be available as IV infusion and the dose level to be administered is 3 milligrams (mg) per kilogram (kg).
Study NCT05229627 — intervention group
Intervention type: DRUG
Intervention: MPH
Description: the drug would be prescribed to patients without any contraindication
Study NCT05229627 — intervention group
Intervention type: DRUG
Intervention: ATX
Description: the drug would be prescribed to patients without any contraindication
Study NCT00768573 — intervention group
Intervention type: DRUG
Intervention: sildenafil
Description: Oral suspension of sildenafil.
Study NCT02731547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Against Tobacco School-Based Intervention
Study NCT01905332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Literacy promoting home based program
Description: The Columbus Metropolitan Library (CML) has an early childhood literacy program, known as Ready to Read. It aims to reach parents and caregivers of children birth to five and share easy literacy-building activities that parents can use at home with their children. Ready to Read Corp members offer 5-6 home visits at no cost, educating parents on early literacy activities in the home.
Study NCT01905332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Literacy Toolkit
Description: Package of books, games, and multi-sensory toys to facilitate the development of emergent literacy skills.
Study NCT00550576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digibind (Fab)
Description: Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.
Study NCT02284386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine SNB
Description: SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
Study NCT02284386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL Infiltration
Description: Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
Study NCT00160342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
Study NCT00160342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
Study NCT00160342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT
Study NCT00160342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT
Study NCT00160342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.30 EE
Study NCT00160342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT
Study NCT00160342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.45 EE
Study NCT02639806 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Study NCT02639806 — intervention group
Intervention type: DRUG
Intervention: Lidocaine
Study NCT02153905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 720,000 IU/kg (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
Study NCT02153905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
Study NCT02153905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study NCT02153905 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
Description: Day 0: MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
Study NCT03839810 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: stochastic resonance electrical stimulation
Description: stochastic resonance electrical stimulation is applied in the upper extremity during motor functional training.~Sham comparator group uses sham stimulation - same electrode location, but no electrical current is applied during motor functional training
Study NCT03839810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stochastic resonance electrical stimulation
Description: stochastic resonance electrical stimulation is applied in the upper extremity during motor functional training.~Sham comparator group uses sham stimulation - same electrode location, but no electrical current is applied during motor functional training
Study NCT03236610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir monotherapy
Description: switching to tenofovir monotherapy
Study NCT03236610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir plus entecavir combination
Description: continuing tenofovir plus entecavir
Study NCT03904940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Contact Insole
Description: Ethyl vinyl acetate insole shaped in the cast of the patient's foot.
Study NCT03904940 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ethyl vinyl acetate flat insole
Description: Flat insole made of the same material ethyl vinyl acetate
Study NCT04528823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strategy 2: Symptom screen, Genexpert and TST
Description: Participants follow an algorithm similar to the standard care, however participants with positive symptom screen and/or positive TST will receive GX (i.e., GX replaces CXR in standard care algorithm). GX positive are considered to have active TB. TST positive and GX negative receive LTBI treatment. If an individual is not able to provide sputum, they will undergo a CXR.
Study NCT04528823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strategy 3:Symptom screen, CXR but NO TST
Description: Participants will receive symptom screening and CXR. No TST will be performed. If CXR abnormal or symptom positive, they undergo microbiological investigation. If the CXR is normal, and/or microbiological investigations negative - they receive LTBI treatment as per national guidelines. If microbiological investigation is positive they will be offered treatment for active TB.
Study NCT05679999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CIMT (Carotid artery intima media thickness measurement)
Description: Carotid artery intima media thickness measurement with ultrasound
Study NCT01667406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 1.6nmol/kg
Description: single kisspeptin dose 1.6 nmol/kg subcutaneously
Study NCT01667406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 3.2nmol/kg
Description: single kisspeptin dose 3.2 nmol/kg subcutaneously
Study NCT01667406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 6.4nmol/kg
Description: single kisspeptin dose 6.4 nmol/kg subcutaneously
Study NCT01667406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 9.6nmol/kg
Description: single kisspeptin dose 9.6 nmol/kg subcutaneously
Study NCT01667406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 12.8nmol/kg
Description: single kisspeptin dose 12.8 nmol/kg subcutaneously
Study NCT01667406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 9.6 nmol/kg double
Description: kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously
Study NCT01667406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 9.6 nmol/kg + saline
Description: kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart
Study NCT01759147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment of acromioclavicular dislocation.
Description: Coracoclavicular ligament repair using autogenous gracilis tendon implanted using an endobutton system containing fibrewires and a single transclavicular, transcoracoid bone tunnel.
Study NCT00916305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Audio video
Description: An audio video modified to mimic noise induced hearing loss after one night at a loud club
Study NCT00916305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unmodified audio video
Description: An audio video with unaltered music
Study NCT00882076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: For Treatment Clofarabine will be administered on Days 2-6 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Clofarabine will be administered on Days 1-4 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
Study NCT00882076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: For Treatment Mitoxantrone will be administered on Days 1-3 at the dose of 8mg/m2 in Cohort 1, 2, 3 and on Days 1-5 for Cohort 4 and on Days 1-3 8mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Mitoxantrone will be administered on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 1, 2 and 3 and on Days 1-4 (4 doses) at the dose of 8mg/m2 in Cohort 4, and on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
Study NCT00882076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: For Treatment Etoposide will be administered on Days 1-5 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Treatment Cohort 1). For Retreatment Etoposide will be administered on Days 1-4 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Retreatment Cohort 1).
Study NCT00943787 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hyperinsulinemic, euglycemic and hypoglycemic clamp
Description: At 21:30h, an overnight insulin infusion was titrated to control the subjects' BG overnight between 100 and 150mg/dL by blood sampling for plasma glucose via a YSI analyzer every 30min and adjusting the rate of insulin infusion as needed. At the beginning of the clamp, the overnight insulin was replaced by an insulin infusion via a Harvard pump given as a 20mU/kg priming over a 10-min period, followed by a constant rate delivery of 1mU/kg/min until the end of the clamp. Blood was sampled for plasma glucose, and glucose was clamped at basal levels for the euglycemic control period of 150min via a variable-rate infusion of 20% dextrose. Then the glucose concentration was lowered at a rate of 1mg/dL/min to a minimum of 50mg/dL, where it was held constant for 30min. Finally, the glucose concentration was increased at a rate of 1mg/dL/min to 90mg/dL, where it was held for an additional 30min. Blood was sampled for epinephrine during euglycemia, hypoglycemia, and recovery.
Study NCT02453243 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safety Planning
Description: Suicide screen-positive patients who are to be discharged from the ED will receive personalized safety planning by a mental health clinician or nurse
Study NCT02453243 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A Lean Implementation Strategy
Description: The Safety Planning Intervention will be implemented using Lean performance improvement strategies.~Sites will be trained on the Safety Planning Intervention and Lean.
Study NCT02520700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daylight and Maquet Power 500 LED surgery light
Description: Comparing the use of daylight and a surgical light (Maquet Power 500 LED surgery light) to activate ALA cream for treatment of actinic keratoses
Study NCT01233661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: short AVD pacing ; prior (stable) programming
Description: short AVD pacing prior (stable) programming
Study NCT03815253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes.
Study NCT03815253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes.
Study NCT01359839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response and Cognitive Behavioral Therapy
Description: This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
Study NCT02229227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
Study NCT02229227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine and Insulin Lispro
Description: Insulin glargine and insulin lispro will be provided as injection pens for SC injection
Study NCT02171884 — intervention group
Intervention type: OTHER
Intervention: Sample of cord blood
Study NCT02171884 — intervention group
Intervention type: OTHER
Intervention: Sample of placenta
Study NCT00160342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.60 MT
Study NCT00293345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00293345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Study NCT00637468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous injection of heparin
Study NCT00637468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous injection of heparin
Study NCT00637468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous injection of acetazolamide
Study NCT00637468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local intra-arterial fibrinolysis
Study NCT00637468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Globe massage
Study NCT00637468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical use of beta-blocker
Study NCT00637468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovolaemic haemodilution
Study NCT00637468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Study NCT02582268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrauterine device TCu 380A
Study NCT02582268 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Trans-abdominal sonography
Study NCT00751322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion of 5 days or less storage age
Description: RBC transfusion of 5 days or less storage age
Study NCT00751322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion of conventional storage age
Description: RBC transfusion of conventional storage age
Study NCT00415701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
Study NCT00415701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Single induction dose of propofol 2%; total dose 1.5 mg/kg
Study NCT00415701 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone
Description: Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
Study NCT00415701 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NaCl 0.9%
Description: NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
Study NCT00415701 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tetracosactin
Description: Diagnostic test, Tetracosactin 250 microg iv
Study NCT01477580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose V180 with low-dose ISCOMATRIX™ adjuvant
Description: Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
Study NCT01477580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant
Description: Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
Study NCT01477580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose V180 (non-adjuvanted)
Description: Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2